Venetoclax may become the best Treatment for Patients who are intolerant to Ibrutinib

Venetoclax may become the best Treatment for Patients who are intolerant to Ibrutinib

ASHReport

3 years
695 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Brian Hill, MD, PhD, of Cleveland Clinic discusses how Venetoclax may be the best novel agent for patients who are intolerant to Ibrutinib at the 58th ASH Annual Meeting in San Diego, CA.
Up Next Autoplay